[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-function-aggravated\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-function-aggravated":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100546748",false,"NCT06398977","Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients","Dapagliflozin Delays the Loss of Residual Renal Function in Patients Undergoing Peritoneal Dialysis: A Single-Center Randomized Open-Label Study","Inclusion Criteria:\n\n* Patients with PD duration between 1 month and 3 months.\n* Patients aged between 18 and 75 years.\n* Voluntary signing of informed consent.\n* Stable use of a maximum tolerated dose of RAAS inhibitors for one month if hypertension is present.\n* Daily urine output ≥ 400ml\u002Fday.\n* Stable PD prescription for one month.\n\nExclusion Criteria:\n\n* Pregnant and lactating women.\n* Patients with type 1 diabetes mellitus.\n* Patients with type 2 diabetes mellitus who have experienced diabetic ketoacidosis in the past.\n* Patients with chronic liver disease, including non-alcoholic fatty liver disease, cirrhosis, ALT \\> 120 IU\u002FL, and other clinically confirmed severe liver diseases.\n* Patients with more than 2 episodes of urinary tract infection in the past six months.\n* Patients with severe allergic reactions (rash or angioedema) to Dapagliflozin.\n* Patients using the following medications: rifampicin, phenytoin.\n* Patients with malignant tumors.\n* Patients who developed peritonitis within one month.\n* Patients undergoing combined hemodialysis treatment.\n* Patients with a willingness for kidney transplantation within six months.\n* Patients with a history of pancreatitis or pancreatic transplantation.\n* Patients who experienced acute coronary syndrome or cerebrovascular events within one month.\n* Hemoglobin level less than 90g\u002FL.","ALL","18 Years","75 Years",{"count":19,"type":20},70,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to explore the role of dagliflozin in preserving the residual renal function(RRF) in peritoneal dialysis (PD) patients.",[26,27,28],"Peritoneal Dialysis Complication","Renal Function Aggravated","Sodium-glucose Co-transporter-2 Inhibitors","RECRUITING","2024-04-30",{"date":32,"type":33},"2024-05-03","ACTUAL",{"date":35,"type":33},"2024-03-11",{"date":37,"type":20},"2026-12-31",{"name":39,"class":40},"Sichuan Academy of Medical Sciences","OTHER",""]